Triastek, Inc.

Triastek, Inc. is a pioneering global leader in 3D printing pharmaceuticals, with a mission to revolutionize the pharmaceutical industry and benefit patients worldwide. Founded in July 2015, the company has developed the Melt Extrusion Deposition (MED®) 3D printing pharmaceutical process, aimed at transforming medication delivery, development, and production through digital product development and continuous manufacturing. Triastek leverages its proprietary 3D printing pharmaceutical technology to design and develop transformative medications, working in collaboration with global pharmaceutical companies to address formulation issues and accelerate the development of new drug products. With its headquarters in China, Triastek recently secured a significant CNY150.00M Series C investment on 28 September 2023, with notable investors including Guoxin Investment, Xiaodong Zheng, and Goldmine Multi-family Office. As the company strives to become the world's most influential intelligent pharmaceutical enterprise, its innovative approach and recent investments position it as a key player in the future of pharmaceutical manufacturing and development.